- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Anastrozole, Letrozole, Goserelin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 421
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 39
- States / cities
- Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Anastrozole
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 33 Years to 96 Years · Female only
- Enrollment
- 4,172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Breast Cancer, Cancer of the Breast, Neoplasms, Breast
- Interventions
- Estrace, Anastrozole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Anastrozole, Letrozole, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 20
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Everolimus, TRC105
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Breast Cancer
- Interventions
- Inavolisib, Placebo, CDK4/6i, Letrozole
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 62
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more
- Conditions
- Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
- Interventions
- PF-07104091 monotherapy dose escalation, PF-07104091 + palbociclib + fulvestrant, PF-07104091 + palbociclib + letrozole, PF-07104091 monotherapy dose expansion (ovarian), PF-07104091 monotherapy dose expansion (SCLC), PF-07104091 + Fulvestrant (post CDK4/6), PF-0704091 + Fulvestrant (post CDK4/6)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 17
- States / cities
- Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more
- Conditions
- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
- Interventions
- Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri
- Conditions
- HER2-positive Breast Cancer, Advanced Breast Cancer
- Interventions
- Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Miami, Florida • Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Vandetanib, Anastrozole
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Breast Cancer, Cancer of the Breast
- Interventions
- DiviTum® TKa assay, Study Care Plans
- Device · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancers
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer Metastatic
- Interventions
- Avasopasem
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 27
- States / cities
- Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more
- Conditions
- Breast Cancer
- Interventions
- leuprolide, letrozole, zoledronic acid
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Boston, Massachusetts • Newton, Massachusetts
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Interventions
- everolimus, anastrozole, letrozole, tamoxifen citrate, fulvestrant, megestrol acetate
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Breast Neoplasms, Neoplasms, Hormone-Dependent
- Interventions
- Atamestane, toremifene, letrozole
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 6
- States / cities
- Greenbrae, California • Saint Joseph, Michigan • Kansas City, Missouri + 3 more
- Conditions
- HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer
- Interventions
- Part 1, Part 2, Part 3
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Newport Beach, California • Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- Text Message Application
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Breast Cancer
- Interventions
- ribociclib (LEE011), Exemestane, Everolimus (RAD001)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more
- Conditions
- Breast Cancer
- Interventions
- Ribociclib, Letrozole, Goserelin, Leuprolide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 71
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more